|
Report No. : |
355601 |
|
Report Date : |
22.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIOS GARDEN HOUSE CHILE SA |
|
|
|
|
Registered Office : |
Avenida Presidente Jorge Alessandri R. N
12.310, San Bernardo, Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
13.02.2001 |
|
|
|
|
Legal Form : |
Sociedad Anónima |
|
|
|
|
Line of Business : |
Subject is a transnational pharmaceutical company
which markets supplements and medicines prepared from herbal extracts,
nutraceuticals, vitamins and minerals. |
|
|
|
|
No. of Employee : |
190 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Growth slowed to 4.2% in 2014. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and 10 other countries in negotiating the Trans-Pacific Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD. In 2014, President Michelle BACHELET introduced tax reforms aimed at delivering her campaign promise to fight inequality and to provide access to education and health care. The reforms are expected to generate additional tax revenues equal to 3% of Chile’s GDP, mostly by increasing corporate tax rates to OECD averages.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
Legal Name: |
LABORATORIOS
GARDEN HOUSE CHILE SA |
|
Trade Name: |
LABORATORIOS
GARDEN HOUSE |
|
RUC: |
96944330-9 |
|
Date Created: |
2001 |
|
Date
Incorporated: |
13/02/2001 |
|
Legal Address: |
Avenida Presidente
Jorge Alessandri R. N 12.310, San Bernardo, Santiago, Chile |
|
Operative
Address: |
Avenida
Presidente Jorge Alessandri R. N 12.310, San Bernardo, Santiago, Chile |
|
Telephone: |
(56-2) 2477
6000 |
|
Fax: |
(56-2) 2477
6002 |
|
Legal Form: |
SOCIEDAD
ANÓNIMA |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Contact: |
Marcelo Rodrigo
Navarro Perez, President |
|
Staff: |
190 |
|
Activity: |
Pharmaceutical
Products Manufacture Industry |
|
|
|
|
Banks: |
Banco Santander
Rio |
|
|
|
|
|
The company
does not disclose its banking details |
History
|
|
|
|
The company was
founded in 2001. |
PRINCIPAL ACTIVITY
|
|
|
|
This is a
transnational pharmaceutical company which markets supplements and medicines
prepared from herbal extracts, nutraceuticals, vitamins and minerals. |
|
Products/Services
description: |
GMP production
of OTC and RX. |
|
Brands: |
Bellatamina |
|
Sales are: |
Wholesale |
|
Clients: |
Pharmaceutical
Industry |
|
Suppliers: |
NA |
|
Operations
area: |
National and
International |
|
The company
imports from |
No import |
|
The company
exports to |
North, Central
and South America |
|
The subject
employs |
190 employees |
|
Payments: |
No Complaints |
LOCATION
|
|
|
Headquarters : |
Avenida
Presidente Jorge Alessandri R. N 12.310, San Bernardo, Santiago, Chile |
|
Branches: |
The company
does not have branches |
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock
exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
The company is
a subsidiary of: |
|
Management: |
Marcelo Rodrigo
Navarro Perez, President |
FINANCIAL INFORMATION
|
|
|
|
This is a private company which does not make its financials public.
The following information has been provided by private sources: |
|
|
|
|
USD 2014 |
|
|
Revenue |
3 400 000 |
|
Cash Flow |
Normal |
LEGAL FILINGS
|
|
|
|
There are no legal
connected to the subject |
SUMMARY
|
|
|
|
This is a
transnational pharmaceutical company which markets supplements and medicines
prepared from herbal extracts, nutraceuticals, vitamins and minerals. |
RISK INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
No Complaints |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
INTERVIEW |
|
|
NAME |
NA |
|
POSITION |
NA |
|
COMMENTS |
We called the
company several times without receiving response. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.32 |
|
|
1 |
Rs.98.99 |
|
Euro |
1 |
Rs.72.13 |
|
USD |
1 |
Rs.66.30 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.